Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Sichuan University

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Changzhou Yinsheng Pharmaceutical Co., Ltd.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Zhifei Fu

Jian Li

Shuhui Chen

Miaorong Luo

Juan Yu

Fei Hong

Jinming Huang

Zhiliang Chen

Tingting Yin

Jinxia Lin

Yichao Zhuang

Longhui Gao

Wei Wang

Jie Li

Guoping Hu

Yuquan Wei

Zhengxia Chen

Chaofeng Long

Xiaoxin Chen

Jianfei Wang

Zhuowei Liu

Cheng Xie

Jikui Sun

Guibai Liang

Zaifang Ren

Zhengwei Li

Jian Wei Li

Jinxiang Zeng

Zhiyi Luo

Shicong Wang

Zhibo Luo

Jiansong Wang

Yingxia Bao

Zhoufan Xie

Luoting Yu

Xin Tao

Limei Yang

Yang Zhang

Peng Li

Yalei Cai

Dongjie Hu

Wu Zhu

Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.

FGFR inhibitor compound in solid form and preparation method therefor

Disclosed are a series of compounds with a nitrogen-containing spiro structure and an application thereof in the preparation of an RET kinase inhibitor. Specifically, disclosed is a compound as shown in formula (II) or a pharmaceutically acceptable salt thereof.

Nitrogen-containing spiro derivative as RET inhibitor

A crystal form of a pyrazin-2(1H)-one compound and a preparation method therefor. The present invention specifically related to a compound of formula (II) and a preparation method for a crystal form of the compound. 

Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor

Provided are crystalline forms of pyrazine-2(1H)-ketone compound and a preparation method thereof; specifically disclosed are a method for preparing the compound of formula (II) and crystalline forms thereof. 

Crystalline form and B crystalline form of pyrazine-2(1H)-ketone compound and preparation method thereof

The present invention disclosed a crystal form of pyrazine-2(1H)-ketone compound and a preparation method therefor. Specifically disclosed is a method for preparing a compound of formula (II) and a crystal form thereof. 

Crystal form D of pyrazine-2(1H)-ketone compound and preparation method therefor

Provided are preparation methods for the chemical compound represented by formula (I) and an intermediate thereof. 

Pyrazine-2(1H)-ketone compound preparation method

Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases. 

Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II): 

Tyrosine kinase inhibitor and pharmaceutical composition comprising same

Provided is a benzofuran analog having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analog. The benzofuran analog has anti-hepatitis C virus activity.

Benzofuran analogue as NS4B inhibitor

Growing community of inventors

Shanghai, China

Zhifei Fu